Pharma companies’ ad spending jumped again last year to $5.6 billion, up from $5.2 billion in 2015, according to Nielsen data (read “Direct-to-Consumer #Pharma Drug Ad Spending at an All-Time High”; http://sco.lt/61NlRp). And Pfizer is in large part to thank.
The drugmaker led the top branded spending for Lyrica, with $174 million on fibromyalgia ads and another $170 million advertising its indication for diabetes-related pain, for a total of $344 million. Lyrica was trailed by another Pfizer drug, rheumatoid arthritis-fighter Xeljanz, at $189 million, and Eli Lilly’s diabetes treatment Trulicity, with $185 million spent. And Pfizer didn't stop there; five of the top nine meds with the highest spending are Pfizer brands.